Multicentre, Prospective Randomized Open Label, Blinded-endpoint (PROBE) Controlled Trial of Early Anticoagulation With Rivaroxaban Versus Standard of Care in Determining Safety at 365 Days in Symptomatic Cerebral Venous Thrombosis
Latest Information Update: 11 Sep 2023
At a glance
- Drugs Rivaroxaban (Primary) ; Low molecular weight heparins; Vitamin K antagonists
- Indications Venous thrombosis
- Focus Adverse reactions
- Acronyms SECRET
- 07 Sep 2023 Results published in the Stroke
- 21 Nov 2022 Status changed from recruiting to completed.
- 27 Sep 2021 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.